welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy
study id #: NCT01847573
condition: Duchenne Muscular Dystrophy
The main purpose of this study is to test the safety and tolerability of different, increasing doses of an experimental medication called HT-100 in boys and young men with Duchenne muscular dystrophy (DMD). The study medication, HT-100, is a medicine that may help promote healthy muscle regeneration, diminish inflammation and the resulting damage to muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream will also be taken.
mechanism of action: Small molecule designed to reduce fibrosis and inflammation
last updated: September 08, 2020
start date: May 2013
estimated completion: March 30, 2016
phase of development: Phase 1/Phase 2
size / enrollment: 17
- Safety and tolerability of administering single and multiple ascending doses of HT-100 in DMD boys [Time Frame: 1 week]
Safety profile by review of adverse events (AEs), physical examination findings, clinical laboratory test results, and other diagnostic testing
- Pharmacokinetic plasma profile of halofuginone after single and multiple dose administration of HT-100 in DMD boys [Time Frame: 1 week]
Halofuginone plasma concentrations
- Safety and tolerability of administering multiple ascending doses of HT-100 in DMD boys over 4 weeks [Time Frame: 4 weeks]
Safety profile by review of AEs, physical examination findings, clinical laboratory test results, and other diagnostic testing
- Early pharmacodynamic signals of HT-100 after 4 weeks of continuous dosing in DMD boys [Time Frame: 4 weeks]
Pharmacodynamic measures relevant to DMD pathology:
• Pulmonary function
• Motor function
• Muscle composition
• Biochemical and imaging markers
• Eligible Sexes: male
• Ambulatory or non-ambulatory
• Diagnosis of DMD with confirmation of minimal to no dystrophin
• Corticosteroid naive or on therapy for at least 12 months (stable dose and regimen)
• Recent, substantial change in use of cardiac medications or medications affecting muscle function
• Inability to undergo magnetic resonance imaging (MRI)
• Significantly compromised cardio-respiratory function
• Prior treatment with another investigational product in past 6 months
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsThis study is designed to assess the eff...
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...